Antibodies 1998: Molecular, Cellular & Clinical Aspects
An International Symposium Sponsored by the Cancer Research Institute
April 22-24, 1998 - Millennium Conference Center - New York, New York

Abstracts:

• Frederick W. Alt. Generally Expressed Gene Products Involved in V(D)J Recombination and DNA Repair. Children’s Hospital and the Center for Blood Research, Harvard Medical School.
• Carlos F. Barbas, III, Christoph Rader, David Segal, Roger Beerli, Birgit Dreier. Targeting Cancer: Proteins and Genes. The Scripps Research Institute.
• Michael C. Carroll. A Critical Role for Complement in Clonal Selection of B Lymphocytes. Harvard Medical School Boston.
• Pamela J. Bjorkman. Functional Consequences of Oligomeric Ribbon Formation for Binding and Transport of IgG by the Neonatal Fc Receptor. California Institute of Technology.
• Zelig Eshhar. Redirecting Genetically Engineered Effector Lymphocytes Using Chimeric Receptors with Antibody-Specificity. Weizmann Institute of Science.
• Douglas T. Fearon. Non-Structural Determinants of Immunogenicity and CD19, CD21, and CD22 of B Lymphocytes. Wellcome Trust Immunology Unit University of Cambridge School of Clinical Medicine Cambridge, UK.
• Marc Feldmann, Fionula Brennan, Ewa Paleolog, Peter Taylor, Ravinder Maini. Anti TNFa Antibody (cA2) Therapy in Rheumatoid Arthritis: Clinical Results and Mechanism of Action. Kennedy Institute of Rheumatology London, UK.
• Martin Gellert, Dale A. Ramsden, Tanya T. Paull, Kevin Hiom, Meni Melek, Mauro Modesti, *Dick C. van Gent. Early and Late Steps in V(D)J Recombination. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda, Maryland *Erasmus University Rotterdam, The Netherlands.
• Christopher C. Goodnow¹, Srinivas Akkaraju, Sarah Townsend¹, James I. Healy, Richard Cornall, Margaret Hibbs², Ashley Dunn², Kevin Otipoby³, Edward Clark³, Richard C. Glynne, David Mack⁴. Switchboards, Rheostats, and Ignition Triggers: How Antigen Receptors Signal Both Immunity and Tolerance in Peripheral Lymphocytes.
  ¹ John Curtin School of Medical Research Canberra, Australia Stanford University Stanford, CA
  ² Ludwig Institute for Cancer Research Melbourne, Australia
  ³ University of Washington Seattle, WA
  ⁴ Affyxmetrix Santa Clara, CA
• Antonio J. Grillo-López. Development of the Anti-CD20 Antibody, Rituxan™, for the Treatment of Low-grade or Follicular Non-Hodgkin’s Lymphoma. IDEC Pharmaceuticals Corporation, San Diego, CA.
• Aya Jakobovits. XenoMouse™ - A Robust Technology for Production of Therapeutic Human Monoclonal Antibodies. Abgenix, Inc., Fremont, CA.
• Garnett Kelsoe. Antigen-Driven V(D)J Recombination in Germinal Center Lymphocytes. University of Maryland School of Medicine, Baltimore, MD.
• M. S. Neuberger. Affinity Maturation of Antibodies. MRC Laboratory of Molecular Biology, Cambridge, UK.
• Michel C. Nussenzweig, Fotini Papavasiliou, Xiao-Feng Qin, Eric Meffre, Heikyung Suh, Paul Cohen. V(D)J Recombination in Mature B Cells: ? A New Mechanism for Antibody Gene Diversification. The Rockefeller University, New York, NY.
• Michael Pfreundschuh, Christoph Renner, Frank Hartmann, Stephen Bauer, Med. Klinik I. Recruitment of Immunological Effector Cells by Bispecific Antibodies: Mechanisms and Clinical Results. Saarland University Medical School Homburg, F.R.G.
• Leonard G. Presta. Humanized Antibodies for Cancer Therapy. Genentech, Inc., S. San Francisco, CA.
• Ellen Puré, William Davis, Hsiu-Ling Li. Syk and Lyn Differentially Regulate BCR Mediated Activation of Akt, p70S6 Kinase, p90Rsk and MAP Kinase. Wistar Institute Philadelphia, PA and Ludwig Institute for Cancer Research New York, NY.
• Jeffrey V. Ravetch. Fc Receptors: Primary Modulators of Antibody Effector Function. The Rockefeller University New York, NY.
• Gert Riethmüller, P. Kufer, T. Raum, R. Lutterbuese, C. Klein, G. Schlimok*, K. Pantel, R.C. Bargou#, B. Doerken#. Adjuvant Cancer Therapy with Bioengineered Antibodies: A Change of Tools and Targets, Does It Make a Difference?. University of Munich, Munich, Germany *Department of Central Oncology, Augsburg #Robert Roessle Hospital, MDC, Berlin.
• Thomas F. Schaible. Clinical Benefits of Anti-TNF cA2 Monoclonal Antibody in Crohn’s Disease and Rheumatoid Arthritis. Centocor Inc., Malvern, PA.
• M.D. Scharff. Somatic V Region Hypermutation in Cultured Antibody-Forming Cells. Albert Einstein College of Medicine, Bronx, NY.
• Andrew M. Scott. Tumor Immunotherapy with Cytotoxic Humanized Antibodies. Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch Austin & Repatriation Medical Centre, Melbourne, Australia.
• E. Sally Ward. Molecular Mechanisms of Serum IgG Homeostasis: Implications for Modulating Pharmacokinetics of Therapeutic Antibodies. University of Texas Southwestern Medical Center, Dallas, TX.